Eucalyptus Oil (1,8-Cineole)
Also called 1,8-cineole, cineole, cineol, eucalyptol, Eucalyptus globulus oil, eucalypti aetheroleum.
Best grade B across 5 graded outcomes Botanical Last checked
The short answer
From 13 sourcesClinical trials of eucalyptus oil mostly test its main constituent, 1,8-cineole, in 200 mg capsules three times daily. Trials in COPD, asthma, acute bronchitis and sinusitis reported benefits, but all came from one research group and two were funded by the company Cassella-med. It is contraindicated under age 2; swallowed oil can cause drowsiness or seizures in children.
Every graded outcome on this page
5 rows · line = participants- BGrade BCOPD exacerbations (frequency, duration, severity)COPDn 242
- CGrade CLung function, asthma symptoms and quality of life (combined)Asthman 247
- CGrade CAcute bronchitis symptom scoreAcute bronchitisn 242
- CGrade CAcute non-purulent rhinosinusitis symptom scoreSinusitisn 152
- DGrade DOral steroid reduction in steroid-dependent asthmaAsthman 32
- 2 more graded outcomes, in the evidence chapter
Key facts
- What it is
- Essential oil from Eucalyptus globulus and related species, rich in 1,8-cineole (eucalyptol)12
- Top studied outcome
- COPD flare-ups: fewer, shorter and milder exacerbations over 6 winter months in 242 patients (grade B); a 2026 network meta-analysis of 18 mucolytic trials ranked cineole first for fewer flare-ups and fewest side effects211
- Who ran the trials
- Every cineole RCT cited here shares one co-author; the COPD and bronchitis trials were funded by Cassella-med23456
- Children
- Contraindicated under 24 months (risk of laryngospasm) and in children with a history of seizures1
- Side effects
- Heartburn, nausea, abdominal pain and diarrhoea by mouth; contact eczema on skin; allergic reactions1
What it is
Eucalyptus oil is the essential oil of eucalyptus leaves; its main constituent, 1,8-cineole (eucalyptol), is sold in capsules.
Forms, side by side
3 forms named in our sources. The rest show what our data holds, and say plainly where it holds nothing yet.
Eucalyptus Oil (1,8-Cineole) forms compared
3 forms| 3 forms | 1,8-cineole capsules (enteric or gut-soluble) | Eucalyptus oil for oral use | Steam inhalation, chest rubs and bath additives |
|---|---|---|---|
| Absorption in people | No head-to-head human data in our sources.2 | No head-to-head human data in our sources.1 | Inhaled or applied to skin.1 |
| GI tolerance | Adverse events similar to placebo in the COPD trial; occasional heartburn or rash.26 | Heartburn, abdominal pain, nausea, vomiting and diarrhoea are listed; caution with inflamed or ulcerated gut.1 | Contact eczema on skin; keep eyes out of the steam and avoid burns from hot water; not on broken or irritated skin.1 |
| Studied for | COPD, asthma, acute bronchitis and sinusitis (200 mg three times daily) | Traditional use for cough with colds (EU monograph: 200 to 600 mg/day, adolescents and adults) | Traditional use for cough with colds and localized muscle pain |
- 1,8-cineole capsules (enteric or gut-soluble)
- Absorption in people
- No head-to-head human data in our sources.2
- Studied for
- COPD, asthma, acute bronchitis and sinusitis (200 mg three times daily)
- Eucalyptus oil for oral use
- Steam inhalation, chest rubs and bath additives
What the human research says
Human trials only, one row per outcome. The form line shows what each trial actually tested. Grades follow our evidence-grading policy.
Trial map
5 graded outcomes, largest study firstAll 5 graded outcomes found an improvement. The largest, a 2012 randomized trial of 247 people on lung function, asthma symptoms and quality of life (combined), found an improvement.
1Lung function, asthma symptoms and quality of life (combined)
Improved · Grade C · RCT, 247 people, 2012
Patients with confirmed asthma (multicentre)
Dose, result and source| Outcome | Found | People | Study | Who was studied |
|---|---|---|---|---|
| Lung function, asthma symptoms and quality of life (combined) | Improved | 247 | Grade C · RCT, 2012 | Patients with confirmed asthma (multicentre) |
| COPD exacerbations (frequency, duration, severity) | Improved | 242 | Grade B · RCT, 2009 | Patients with stable COPD on standard medication (multicentre) |
| Acute bronchitis symptom score | Improved | 242 | Grade C · RCT, 2013 | Patients with acute bronchitis (multicentre) |
| Acute non-purulent rhinosinusitis symptom score | Improved | 152 | Grade C · RCT, 2004 | Patients with acute non-purulent rhinosinusitis |
| Oral steroid reduction in steroid-dependent asthma | Improved | 32 | Grade D · RCT, 2003 | Patients with severe, steroid-dependent bronchial asthma |
Every graded row
5 rowsShowing 5 of 5 outcomes. Human trials only.
BGrade BCOPD exacerbations (frequency, duration, severity)COPDImprovedRCT
n 242 · 2009
Improved Exacerbations were significantly less frequent, shorter and less severe than on placebo. Lung function, breathlessness and quality of life also improved; adverse events were similar in both groups.
- Design
- RCT, n = 242, 2009
- Population
- Patients with stable COPD on standard medication (multicentre)
- Form
- 1,8-cineole capsules as add-on therapy
- Dose
- 200 mg three times daily
- Duration
- 6 months (winter)
- Source
- Reference 2 · PubMed 19624838 (opens PubMed)
CGrade CLung function, asthma symptoms and quality of life (combined)AsthmaImprovedRCT
n 247 · 2012
Improved The combined outcome favoured cineole (p = .0027); individual measures were each only modestly significant (FEV1 p = .0398, symptoms p = .0325, quality of life p = .0475).
- Design
- RCT, n = 247, 2012
- Population
- Patients with confirmed asthma (multicentre)
- Form
- 1,8-cineole capsules as add-on therapy
- Dose
- 200 mg three times daily
- Duration
- 6 months
- Source
- Reference 3 · PubMed 22978309 (opens PubMed)
CGrade CAcute bronchitis symptom scoreAcute bronchitisImprovedRCT
n 242 · 2013
Improved After 4 days the bronchitis sum score improved more than on placebo (p = 0.0383), with fewer coughing fits (p = 0.0001).
- Design
- RCT, n = 242, 2013
- Population
- Patients with acute bronchitis (multicentre)
- Form
- 1,8-cineole capsules
- Dose
- 200 mg three times daily
- Duration
- 10 days
- Source
- Reference 4 · PubMed 24261680 (opens PubMed)
CGrade CAcute non-purulent rhinosinusitis symptom scoreSinusitisImprovedRCT
n 152 · 2004
Improved Mean symptom score fell from 15.6 to 3.0 on cineole vs 9.2 on placebo by day 7. Two patients had possibly related heartburn or rash.
- Design
- RCT, n = 152, 2004
- Population
- Patients with acute non-purulent rhinosinusitis
- Form
- 1,8-cineole capsules
- Dose
- Two 100 mg capsules three times daily (600 mg/day)
- Duration
- 7 days
- Source
- Reference 6 · PubMed 15064633 (opens PubMed)
DGrade DOral steroid reduction in steroid-dependent asthmaAsthmaImprovedRCT
n 32 · 2003
Improved Prednisolone could be cut by 36% on cineole vs 7% on placebo (P = 0.006); 12 of 16 vs 4 of 16 patients reduced their oral steroid.
- Design
- RCT, n = 32, 2003
- Population
- Patients with severe, steroid-dependent bronchial asthma
- Form
- 1,8-cineole in small gut-soluble capsules
- Dose
- 200 mg three times daily
- Duration
- 12 weeks
- Source
- Reference 5 · PubMed 12645832 (opens PubMed)
Common cold: timing study without a placebo
1 noteHuman data that cannot be graded as an outcome here.
- Earlier start, milder cold
- In an open-label, non-randomized study, 329 adults who caught a cold took 200 mg cineole three times daily for up to 15 days. Those who started within 12 hours had a 38% lower symptom burden and recovered in 8.9 days versus 10.7 days when started after 24 hours; 4.3% had side effects possibly related to cineole. With no placebo group, this compares start times, not cineole against nothing.13
What the numbers add up to
Each point is worked out from the data and the sources numbered on this page, with the arithmetic shown under it. It adds no new data and is not medical advice.
Studied doses
Doses used in research, shown against the official limits. They describe the studies, not a recommendation for you.
Studied doses in research, not advice. These are amounts used in research, not personal advice. Your clinician or pharmacist can say what fits you.
Doses studied in human trials
Interactions and safety
Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.
Interactions
0 agentsNone found in our sources.
Check with what you take
Kept on this device onlyAdd what you take. We list every interaction our evidence profiles cite between Eucalyptus Oil and your picks, and between your picks.
- Loading names…
Add a supplement or medicine you take to check it against Eucalyptus Oil.
Starting from one medicine? The interaction checker rates how serious each pair is, on a curated list of 19 entries for 11 medicines. This cabinet has no severity rating: it lists every interaction row our supplement pages cite.
Who should be careful
7 groups- Infants and young children
- Contraindicated under 24 months because 1,8-cineole products can trigger laryngospasm. Oral use under 12 and inhalation under 3 have not been established.1
- Accidental swallowing by children
- Keep the oil out of children's reach. In 109 young children admitted to a Melbourne hospital after swallowing eucalyptus oil, 28% had a depressed conscious state; the authors warn that 2 to 3 ml of pure oil can cause drowsiness and 5 ml or more significant loss of consciousness. All recovered. In a Victorian survey, 74% of young children who swallowed or may have swallowed it reached it through a home vaporiser, most often at ground level. Seizures have followed oil drops given by mouth in water or milk.7108
- Children with seizures
- Contraindicated in children with a history of seizures, febrile or not. Eucalyptus oil has triggered first seizures and breakthrough seizures in children with epilepsy, after swallowing, inhalation or skin use.189
- Allergy
- Contraindicated with hypersensitivity to eucalyptus oil or 1,8-cineole; severe systemic allergic reactions have been reported.1
- Stomach or bowel inflammation
- Use with caution in inflamed or ulcerated conditions of the gastrointestinal tract.1
- Pregnancy and breastfeeding
- Safety has not been established, and the EU monograph does not recommend use during pregnancy or breastfeeding. LactMed has no entry for eucalyptus oil or cineole (its 'oil of lemon eucalyptus' entry covers a different insect-repellent product).1
- Worsening breathing
- See a doctor if shortness of breath, fever or purulent sputum appears, or if cough lasts longer than a week.1
Safety
5 notesMostly mild stomach effects in adults; real hazards for small children and in overdose.
- By mouth
- Heartburn, abdominal pain, nausea, vomiting and diarrhoea are listed side effects.1
- Overdose
- Doses above those recommended can cause vomiting, breathing problems, CNS depression, loss of consciousness, convulsions, ataxia and constricted pupils. In young children, swallowing a few millilitres of pure oil has caused drowsiness and, at 5 ml or more, significant loss of consciousness.17
- Seizures
- In a prospective series of 17 children (median age 3.75 years) who had generalized seizures after eucalyptus oil drops by mouth, seizures began a median 20 minutes after exposure and none recurred over 6 to 9 months. A review of 110 published cases (49 children) found inhalation the most common route; adults were less likely than children to have prolonged or repeated seizures needing intensive care.89
- Skin
- Contact eczema can occur; do not apply to broken or irritated skin, and wash hands to avoid eye irritation.1
- Interactions
- The EU monograph reports no known drug interactions, and no interaction studies or case reports turned up in our 2026 PubMed search; LiverTox has no eucalyptus entry.1
How to read the label
What to check on the Supplement Facts panel.
How to read the label
3 checksCineole vs whole oil
Label dose vs clinical dose
Keep it away from small children
Products are contraindicated under 2 years, including chest rubs and inhalations.1
Frequently asked questions
Short answers to common questions; the numbers link to the sources below.
Common questions
7 answersDoes cineole help COPD?
In one 242-patient trial, 200 mg three times daily as add-on therapy for 6 winter months reduced the frequency, length and severity of flare-ups. The trial was company-funded and has not been independently repeated.2
Does it help a chest cold or sinus infection?
Is eucalyptus oil safe for babies?
No. EU regulators contraindicate it under 24 months because cineole products can cause laryngospasm, and in children with a history of seizures.1
What happens if someone swallows too much?
Can eucalyptus oil cause seizures?
Yes, rarely. Seizures have followed swallowing, inhaling or rubbing on eucalyptus oil. In 17 children who had seizures after oral drops, fits began a median 20 minutes later; a review of 110 cases found children more likely than adults to need intensive care. The EU monograph rules it out for children with a history of seizures.891
Is it safe to use a eucalyptus vaporiser around young children?
Sources
13 sources: trial abstracts, NIH fact sheets and reference databases. Numbers in the text link here.
Sources cited on this page
13 sources- 1European Union herbal monograph on Eucalyptus globulus Labill.; Eucalyptus polybractea R.T. Baker; Eucalyptus smithii R.T. Baker, aetheroleum (Revision 1, EMA/HMPC/320292/2023)Guideline European Medicines Agency (HMPC), 2024 · ema.europa.eu
- 2Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial.RCT Respir Res, 2009 · PMID 19624838
- 3Patients with asthma benefit from concomitant therapy with cineole: a placebo-controlled, double-blind trial.RCT J Asthma, 2012 · PMID 22978309
- 4Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial.RCT Cough, 2013 · PMID 24261680
- 5Anti-inflammatory activity of 1.8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial.RCT Respir Med, 2003 · PMID 12645832
- 6Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial.RCT Laryngoscope, 2004 · PMID 15064633
- 7Clinical effects and management of eucalyptus oil ingestion in infants and young children.Observational Med J Aust, 1995 · PMID 7651249
- 8Eucalyptus Oil-Induced Seizures in Children: A Single-Center Prospective Study.Observational Cureus, 2021 · PMID 33927923
- 9Clinico-laboratory characteristics and outcome of patients with eucalyptus oil-induced/provoked seizures: A case series and systematic review of the published patients.Systematic review Trop Doct, 2021 · PMID 34282989
- 10Eucalyptus oil poisoning among young children: mechanisms of access and the potential for prevention.Observational Aust N Z J Public Health, 1997 · PMID 9270157
- 11Efficacy and safety of mucolytic agents in patients with chronic obstructive pulmonary disease: a systematic review and network meta-analysis.Meta-analysis BMC Pulm Med, 2026 · PMID 41688985
- 12Effects of Essential Oils in the Treatment of Acute Rhinosinusitis: A Systematic Review.Systematic review Laryngoscope Investig Otolaryngol, 2025 · PMID 40575453
- 13The impact of cineole treatment timing on common cold duration and symptoms: Non-randomized exploratory clinical trial.Open-label trial PLoS One, 2024 · PMID 38236839
What changed
Every dated change to this page: what changed, who made it and why.
Change log
3 entries| Date | Change | Who and why |
|---|---|---|
| summary, key facts, evidence notes, research notes, who should avoid, safety, FAQ, questions, related | Added child-poisoning data: a 2021 prospective series of 17 children with seizures after oral eucalyptus oil drops, a 2021 review of 110 published seizure cases (49 children) and a 1997 Victorian survey showing most young children reached the oil through home vaporisers; these now feed the summary, key facts, safety notes and two new FAQ items. Added a 2026 network meta-analysis of COPD mucolytics (cineole ranked best for fewer flare-ups and side effects) and a 2025 rhinosinusitis systematic review to the evidence notes, and a 2024 open-label common-cold timing study as an ungraded research note (no placebo group). Pregnancy note now records that LactMed has no eucalyptus oil entry. Interactions re-checked: none in the EU monograph or PubMed; LiverTox has no entry. Not added as rows: a 2025 trial of a combined eucalyptol-limonene-pinene capsule (not cineole alone). | Writer: Kymata Health EditorialTrigger: A–Z audit against docs/supplements/AUDIT-STANDARD.md |
| all | Initial editorial evidence review (first draft). Every PMID checked against NCBI E-utilities esummary (title and year) and each cited abstract read; numbers taken from the abstracts. No retractions or errata linked to the cited PMIDs. Funding: the COPD (2009) and acute bronchitis (2013) trials state a grant from Cassella-med, Cologne; the other three trials do not state funding in their abstracts and share the co-author U. Dethlefsen. Safety, interaction and pregnancy text come only from the EMA herbal monograph (Revision 1, adopted 20 November 2024; no interactions reported). No product links. | Writer: Kymata Health EditorialTrigger: new page |
| evidence and safety | Adversarial review: added child ingestion toxicity from a 109-child hospital series (PMID 7651249) to the summary, key facts, who-should-avoid, safety and FAQ; named U. Dethlefsen's affiliation (MKL Institute of Clinical Research). | Writer: Kymata Health EditorialTrigger: adversarial review |
Supplement & Nutrient Encyclopedia. Educational information only; it is not medical advice and does not replace a clinician. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Statements about supplements have not been evaluated by the FDA.